Adherence
Adherence to GLP-1 receptor agonist (GLP-1RA) therapy significantly enhances weight loss in patients with type 2 diabetes, whereas poor adherence attenuates this benefit.
If you are prescribed a GLP-1RA for type 2 diabetes, taking it consistently as prescribed is critical for losing weight. Patients who adhere to the medication lose significantly more weight than those who do not. To maximize benefits, focus on maintaining high adherence to your prescribed regimen.
Adherent GLP-1RA-treated patients lost 1.73 kg more than poorly adherent patients (P < 0.01)... Adherent GLP-1 patients lost 1.73 kg more than poorly adherent patients, and adherent SU patients gained 1.11 kg more than poorly adherent patients (all P < 0.01).
Why this rating
Large real-world observational study (n=833 GLP-1RA) with regression adjustment, though not a randomized controlled trial.
Source
Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
Ginger Smith Carls et al. · Obesity Science & Practice · 2017
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →